Edward Pershing - Sep 23, 2022 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Role
Director
Signature
/s/ Edward Pershing
Stock symbol
PVCT
Transactions as of
Sep 23, 2022
Transactions value $
$242,500
Form type
4
Date filed
10/28/2022, 01:31 PM
Previous filing
Oct 5, 2023
Next filing
Nov 2, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PVCT 8% Unsecured Convertible Promissory Note due 2023 Award $75K $75K Sep 23, 2022 Series D-1 Convertible Preferred Stock 26.2K $2.86 Direct F1, F2
transaction PVCT 8% Unsecured Convertible Promissory Note due 2023 Award $110K $185K Sep 30, 2022 Series D-1 Convertible Preferred Stock 38.4K $2.86 Direct F1, F2
transaction PVCT 8% Unsecured Convertible Promissory Note due 2023 Award $50K $235K Oct 14, 2022 Series D-1 Convertible Preferred Stock 17.5K $2.86 Direct F1, F2
transaction PVCT 8% Unsecured Convertible Promissory Note due 2023 Award $7.5K $243K Oct 27, 2022 Series D-1 Convertible Preferred Stock 2.62K $2.86 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person may voluntarily elect to convert the outstanding principal and interest of the 8% unsecured convertible promissory note due 2023 (the "Note") at any time while the Note is outstanding into shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Preferred Stock") at a price per share equal to $2.862. The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the Note. The Note was issued pursuant to the Issuer's 2022 Financing.
F2 Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Preferred Stock.